Caspian Journal of Internal Medicine
Babol University of Medical Sciences
شنبه 29 آذر 1404
[Archive]
دوره 17، شماره 1 - ( 11-1404 )
جلد 17 شماره 1 صفحات 0-3 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khaksari M N, Meghdadi M, Rostami M, Khoshnegah Z, Boroumand-Noughabi S, Bazi A, et al . Frequency of prognostically important acute myeloid leukemia mutations in the Iranian population: A systematic review and meta-analysis. Caspian J Intern Med 2026; 17 (1) :3-0
URL: http://caspjim.com/article-1-4698-fa.html
URL: http://caspjim.com/article-1-4698-fa.html
Frequency of prognostically important acute myeloid leukemia mutations in the Iranian population: A systematic review and meta-analysis. . 1404; 17 (1) :3-0
چکیده: (30 مشاهده)
Background: The geographic diversity of molecular genetic abnormalities in AML can help understand the genetic and environmental factors involved in the development of leukemia. In addition, high-risk groups can be recognized by identifying common mutations in AML patients, and appropriate treatment based on the type of mutation can be adopted. This systematic study and meta-analysis analyzed the common mutations in AML patients in Iran.
Methods: In this systematic study, common mutations in Iranian AML patients were comprehensively examined across four databases: PubMed, Scopus, Web of Science, and Magiran, from 1980 to 2024, following the PRISMA guidelines. Meta-Analysis Version 2 (CMA2 was used for data analysis, and I²-test values greater than 50% were considered to indicate high heterogeneity among the studies.
Result: By reviewing 40 articles, it was found that the prevalence of FLT3-ITD mutation was 21.9% (CI: 19.19 - 24.1) in 34 studies (3,152 AML cases), FLT3-TKD mutation 6.6% (CI: 4.7 - 9.3) in 19 studies, NPM1 mutation 19% (CI: 15.9-22.6) in 18 studies DNMT3A mutation 13.9% (CI: 11.1 - 17.2) in 5 studies, CEBPA mutation was 18.5% (CI: 10.3 - 31) in 5 studies, and WT-1 mutation prevalence was 8.2% (CI: 5.6-11.8)in 4 studies. Other mutations investigated in the studies included NRAS, IDH1, IDH2, TET2, c-kit, ASXL1, and RUNX1.
Conclusion: Studies have shown that the FLT3-ITD mutation is the most prevalent mutation among Iranian AML patients. Following this, the most common mutations identified were NPM1, CEBPA, DNMT3A, and WT1, in that order.
Methods: In this systematic study, common mutations in Iranian AML patients were comprehensively examined across four databases: PubMed, Scopus, Web of Science, and Magiran, from 1980 to 2024, following the PRISMA guidelines. Meta-Analysis Version 2 (CMA2 was used for data analysis, and I²-test values greater than 50% were considered to indicate high heterogeneity among the studies.
Result: By reviewing 40 articles, it was found that the prevalence of FLT3-ITD mutation was 21.9% (CI: 19.19 - 24.1) in 34 studies (3,152 AML cases), FLT3-TKD mutation 6.6% (CI: 4.7 - 9.3) in 19 studies, NPM1 mutation 19% (CI: 15.9-22.6) in 18 studies DNMT3A mutation 13.9% (CI: 11.1 - 17.2) in 5 studies, CEBPA mutation was 18.5% (CI: 10.3 - 31) in 5 studies, and WT-1 mutation prevalence was 8.2% (CI: 5.6-11.8)in 4 studies. Other mutations investigated in the studies included NRAS, IDH1, IDH2, TET2, c-kit, ASXL1, and RUNX1.
Conclusion: Studies have shown that the FLT3-ITD mutation is the most prevalent mutation among Iranian AML patients. Following this, the most common mutations identified were NPM1, CEBPA, DNMT3A, and WT1, in that order.
نوع مطالعه: Review Article |
موضوع مقاله:
Hematology
دریافت: 1403/12/1 | پذیرش: 1404/4/28 | انتشار: 1404/10/21
دریافت: 1403/12/1 | پذیرش: 1404/4/28 | انتشار: 1404/10/21
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
